FORM 4

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box if no longer subject to

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

washington, D.	C. 20549

<b>STATEMENT</b>	OF CHANGES	IN BENEFICIAL	<b>OWNERSHIP</b>

**OMB APPROVAL** 3235-0287 Estimated average burden 0.5

hours per response

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  SNODGRASS H. RALPH					2. Issuer Name <b>and</b> Ticker or Trading Symbol VistaGen Therapeutics, Inc. [VTGN]						(Che	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Last) (First) (Middle) C/O VISTAGEN THERAPEUTICS, INC. 343 ALLERTON AVENUE					3. Date of Earliest Transaction (Month/Day/Year) 08/05/2018								X Director X Officer (give title below) PRES./CHIEF SCIENTI				pecify
(Street) SOUTH FRANCI	SCO	A tate)	94080 (Zip)	4.	If Ame	endment, [	Date o	f Original Fi	led (Mo	nth/Da	y/Year)	Line	Form fil	led by One led by Mor	Repo	(Check Appl rting Person One Reporti	
(- 3)			ble I - Non-De	rivativ	ve Se	ecurities	s Ac	auired C	isnos	sed o	f or Re	neficially	Owned				
1. Title of Security (Instr. 3) 2. T Date				ZA. Deemed Execution Date if any (Month/Day/Yea		Date,	Code (Instr. 8)		ties Acquire I Of (D) (Ins	tr. 3, 4 and 5	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Direct III	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Table II - Der (e.g						spose	d of,	or Bene	eficially (	(Instr. 3 a	nd 4)			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any (Month/Day/Year) 8	4. Transa Code ( 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expira Date	ation	Title	Amount or Number of Shares		Transaction(: (Instr. 4)			
Stock Option (Right to Buy)	\$1.27	08/05/2018		A		125,000		(1)	08/05	/2028	Common Stock	125,000	\$0	125,00	00	D	

## **Explanation of Responses:**

1. 25% of the Shares subject to the Option shall vest on Vesting Start Date August 5, 2018, and 1/24th of the remaining Shares subject to the Option shall vest on each monthly anniversary of the Vesting Start Date

/s/ Jerrold D. Dotson, Attorney- 08/06/2018

in-Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.